Original Research

How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria

Published in: Volume 2 / Year 2013 / Issue 2
Author(s): ,
Page: 65-75

Objective: To analyse similarities and differences between activities carried out by Austrian sickness funds to encourage more rational use of medicines, including increasing generics uptake. Methods: Semi-structured interviews with pharmacoeconomic… Read More »

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation

Published in: Volume 2 / Year 2013 / Issue 1
Author(s): , ,
Page: 13-9

Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself.… Read More »

Saving money in the European healthcare systems with biosimilars

Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s): , , ,
Page: 120-6

Introduction: The use of biotechnological manufactured drugs, or biologicals, has increased massively over the past few years. Used especially in the treatment of cancer and other severe diseases, biologicals incur high… Read More »

European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution

Published in: Volume 9 / Year 2020 / Issue 3
Author(s): ,
Page: 116-24

Introduction: The European Union (EU) and the European Medicines Agency (EMA) have led the development of a regulatory framework for biosimilars since 2004. By end of December 2019, 64 biosimilars… Read More »

US prescribers’ attitudes and perceptions about biosimilars

Author byline as per print journal: Ralph McKibbin, MD; Michael S Reilly, Esq Introduction: In the United States (US), a legal framework for approving biosimilars was established via the Biologics Price… Read More »

Social trust, economic incentives, and regional variation in the adoption of biosimilars in Italy and Germany

Author byline as per print journal: James C. Robinson, PhD, MPH Introduction/Study Objectives: Adoption of biosimilars has fallen below projections, despite the vigorous implementation of economic incentives, thereby highlighting the importance… Read More »

Development of Ph. Eur. standards for therapeutic monoclonal antibodies: infliximab case study

Keywords: Monoclonal antibodies, pharmacopoeia, infliximab, public standards, flexibility Author byline as per print journal: M Buda, PhD Abstract: This article describes the European Pharmacopoeia exploratory study on infliximab as a test case… Read More »

Page 6 of 6 1 ... « Previous2 3 4 5 6
Go Back Print